Related Experiment Video
Updated: Dec 12, 2025
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Catheter vs thoracoscopic ablation for atrial fibrillation: Meta-analysis of randomized trials
Tom Kai Ming Wang1,2, Yi-Wen Becky Liao1,3, Michael Tzu Min Wang1
1Green Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand.
Insights
Catheter ablation (CA) for atrial fibrillation (AF) shows lower efficacy but better safety than thoracoscopic ablation (TA). CA remains the preferred first-line treatment for AF, with TA reserved for specific cases.
Area of Science:
- Cardiology
- Medical Technology
Background:
- Atrial fibrillation (AF) is a common cardiac arrhythmia.
- Catheter ablation (CA) and thoracoscopic ablation (TA) are common treatment strategies for AF.
Purpose of the Study:
- To compare the efficacy and safety of CA versus TA for treating AF.
- To inform clinical decision-making regarding AF ablation strategies.
Main Methods:
- A meta-analysis of randomized trials was conducted.
- Searched PubMed, Embase, and Cochrane databases up to December 31, 2019.
- Pooled analysis of data from six trials involving 465 patients.
Main Results:
- One-year AF recurrence was higher with CA (46%) compared to TA (26%).
- Total adverse events were significantly lower with CA (10%) versus TA (25%).
- Odds ratio for recurrence: 2.90 (95% CI 1.32-6.38); Odds ratio for adverse events: 0.35 (95% CI 0.14-0.86).
Conclusions:
- Catheter ablation (CA) demonstrates lower efficacy but superior safety compared to thoracoscopic ablation (TA) for AF.
- CA should be the primary treatment strategy for AF.
- Thoracoscopic ablation (TA) should be reserved for CA-resistant patients requiring strict rhythm control.
Background:
We meta-analyzed the efficacy and safety of catheter (CA) vs thoracoscopic (TA) ablation for atrial fibrillation (AF).
Methods:
PubMed, Embase, and Cochrane databases were searched until 31/12/2019 for relevant randomized trials and subsequent pooled analyses.
Results:
In six trials totaling 465 patients (254 CA/211 TA), 1-year AF recurrences were higher for CA (46% vs 26%, odds ratio 2.90 [95% CI 1.32-6.38]), whereas total adverse events were lower (10% vs 25%, 0.35 [0.14-0.86], respectively).
Conclusion:
CA has lower efficacy but higher safety than TA. CA should remain the first-line AF ablation strategy, and TA reserved for selected CA-resistant patients where rhythm control is clinically necessary.
